MBX vs. ENTA

Last updated Jun 9, 2026

MBX (MBX Biosciences, Inc) and ENTA (Enanta Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, MBX returned 155.06% vs 48.19% for ENTA. At a 0.28 correlation, their price movements are largely independent.

Performance

MBX vs. ENTA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MBX Biosciences, Inc (MBX) and Enanta Pharmaceuticals, Inc. (ENTA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, MBX achieves a -8.05% return, which is significantly higher than ENTA's -29.80% return.

MBX

• 1D: -4.23%
• 1M: -29.21%
• YTD: -8.05%
• 6M: -7.61%
• 1Y: 155.06%
• 3Y*: —
• 5Y*: —
• 10Y*: —

ENTA

• 1D: -1.86%
• 1M: -27.84%
• YTD: -29.80%
• 6M: -21.93%
• 1Y: 48.19%
• 3Y*: -24.76%
• 5Y*: -25.36%
• 10Y*: -7.18%

*Multi-year figures are annualized to reflect compound growth (CAGR)

MBX vs. ENTA - Yearly Performance Comparison

	2026 (YTD)	2025	2024
MBX MBX Biosciences, Inc	-8.05%	71.13%	-22.07%
ENTA Enanta Pharmaceuticals, Inc.	-29.80%	174.26%	-53.74%

Correlation

The correlation between MBX and ENTA is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.28
Correlation (All Time) Calculated using the full available price history since Sep 16, 2024	0.28

Fundamentals

Market Cap MBX : $1.35B ENTA : $319.83M
EPS MBX : -$2.30 ENTA : -$2.67
PB Ratio MBX : 3.09 ENTA : 2.77
Total Revenue (TTM) MBX : $0.00 ENTA : $69.21M
Gross Profit (TTM) MBX : -$160.00K ENTA : $33.44M
EBITDA (TTM) MBX : -$96.31M ENTA : -$61.85M

Return for Risk

MBX vs. ENTA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MBX

MBX Risk / Return Rank: 85
MBX Sharpe Ratio Rank: 77
MBX Sortino Ratio Rank: 88
MBX Omega Ratio Rank: 84
MBX Calmar Ratio Rank: 89
MBX Martin Ratio Rank: 84

ENTA

ENTA Risk / Return Rank: 68
ENTA Sharpe Ratio Rank: 58
ENTA Sortino Ratio Rank: 74
ENTA Omega Ratio Rank: 73
ENTA Calmar Ratio Rank: 69
ENTA Martin Ratio Rank: 66

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MBX vs. ENTA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MBX Biosciences, Inc (MBX) and Enanta Pharmaceuticals, Inc. (ENTA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MBX	ENTA	Difference
Sharpe ratio: Return per unit of total volatility	1.17	0.44	+0.73
Sortino ratio: Return per unit of downside risk	2.91	1.88	+1.03
Omega ratio: Gain probability vs. loss probability	1.33	1.24	+0.09
Calmar ratio: Return relative to maximum drawdown	4.15	1.41	+2.74
Martin ratio: Return relative to average drawdown	7.99	2.72	+5.26
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MBX vs. ENTA - Sharpe Ratio Comparison

The current MBX Sharpe Ratio is 1.17, which is higher than the ENTA Sharpe Ratio of 0.44. The chart below compares the historical Sharpe Ratios of MBX and ENTA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	MBX	ENTA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.17	0.44	+0.73
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.35	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.12	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.11	-0.05	+0.16

Drawdowns

MBX vs. ENTA - Drawdown Comparison

The maximum MBX drawdown since its inception was -77.71%, smaller than the maximum ENTA drawdown of -96.63%. Use the drawdown chart below to compare losses from any high point for MBX and ENTA.

Drawdown Indicators

	MBX	ENTA	Difference
Max Drawdown Largest peak-to-trough decline	-77.71%	-96.63%	+18.92%
Max Drawdown (1Y) Largest decline over 1 year	-37.60%	-34.30%	-3.30%
Max Drawdown (3Y) Largest decline over 3 years	—	-83.61%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-95.62%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-96.63%	—
Current Drawdown Current decline from peak	-32.78%	-91.24%	+58.46%
Average Drawdown Average peak-to-trough decline	-35.04%	-49.23%	+14.19%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.50%	17.76%	+1.74%

Volatility

MBX vs. ENTA - Volatility Comparison

MBX Biosciences, Inc (MBX) has a higher volatility of 23.40% compared to Enanta Pharmaceuticals, Inc. (ENTA) at 13.36%. This indicates that MBX's price experiences larger fluctuations and is considered to be riskier than ENTA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MBX	ENTA	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.40%	13.36%	+10.04%
Volatility (6M) Calculated over the trailing 6-month period	57.78%	35.53%	+22.25%
Volatility (1Y) Calculated over the trailing 1-year period	133.96%	109.93%	+24.03%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	118.74%	73.36%	+45.38%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	118.74%	60.70%	+58.04%

Dividends

MBX vs. ENTA - Dividend Comparison

Neither MBX nor ENTA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both MBX and ENTA in my portfolio?

MBX and ENTA have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, MBX or ENTA?

MBX has higher volatility (23.40%) compared to ENTA (13.36%). In terms of maximum drawdown, MBX dropped -77.71% vs ENTA's -96.63%.

Which has better risk-adjusted returns?

MBX currently has the higher Sharpe Ratio (1.17 vs 0.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.